Kazia Therapeutics Announces Three Patients With Metastatic Triple-Negative Breast Cancer With Paxalisib-Based Regimens Have Demonstrated Meaningful Clinical Responses In Phase 1b Trial Of Paxalisib In Combination With Pembrolizumab And Chemotherapy

Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC).

To date, three patients with metastatic TNBC treated with paxalisib-based regimens have demonstrated meaningful clinical responses, including two partial responses (PRs) in trial participants and one confirmed complete metabolic response (CR) in a patient treated under an expanded access program.